Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGG1 | O15527 | 1/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | RXRB | P28702 | 1/20 | 0.40 |
| ▸ | RXRG | P48443 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9875360 | 0.86 | OGG1 (0.54) | OGG1TRPV1KMT2AL3MBTL1BCHE | |
| SCHEMBL29879678 | 0.83 | OGG1 (0.51) | OGG1TRPV1KMT2AL3MBTL1BCHE | |
| SCHEMBL18335371 | 0.83 | OGG1 (0.55) | OGG1TRPV1KMT2AL3MBTL1BCHE | |
| SCHEMBL29137024 | 0.83 | OGG1 (0.51) | OGG1TRPV1KMT2AL3MBTL1BCHE | |
| SCHEMBL11338531 | 0.80 | HTT (0.60) | OGG1KMT2AKDM4EHTT | |
| SCHEMBL31344417 | 0.80 | P2RX4 (0.48) | OGG1KMT2AL3MBTL1BCHEHPGD | |
| SCHEMBL20296798 | 0.79 | OGG1 (0.46) | OGG1TRPV1KMT2AL3MBTL1BCHE | |
| SCHEMBL662703 | 0.78 | ELANE (0.53) | KMT2AL3MBTL1HPGDALOX15ALDH1A1 | |
| SCHEMBL16161640 | 0.77 | BCHE (0.45) | OGG1KMT2ABCHEKDM4EHPGD | |
| SCHEMBL11335792 | 0.77 | OGG1 (0.54) | OGG1KMT2AL3MBTL1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2613783-B1 | METHODS FOR THE TREATMENT OR PROPHYLAXIS OF THROMBOSIS OR EMBOLISM | IPCA LABORATORIES LTD (IN) | 2019-06-12 | — | — | EP | disclosed |
| US-9321785-B2 | Methods for the treatment or prophylaxis of thrombosis or embolism | IPCA LABORATORIES LIMITED (IN) | 2016-04-26 | — | — | US | disclosed |
| US-20150307513-A1 | COMPOSITION FOR THE TREATMENT OR PROPHYLAXIS OF THROMBOSIS OR EMBOLISM | IPCA LAB LTD (IN) | 2015-10-29 | — | — | US | disclosed |
| US-20140018331-A1 | METHODS FOR THE TREATMENT OR PROPHYLAXIS OF THROMBOSIS OR EMBOLISM | IPCA LABORATORIES LIMITED (IN) | 2014-01-16 | — | — | US | disclosed |
| US-8541422-B2 | Methods for the treatment or prophylaxis of thrombosis or embolism | IPCA LABORATORIES LIMITED (IN) | 2013-09-24 | — | — | US | disclosed |
| EP-2613783-A1 | METHODS FOR THE TREATMENT OR PROPHYLAXIS OF THROMBOSIS OR EMBOLISM | IPCA Laboratories Limited (IN) | 2013-07-17 | — | — | EP | disclosed |
| US-20120053157-A1 | METHODS FOR THE TREATMENT OR PROPHYLAXIS OF THROMBOSIS OR EMBOLISM | IPCA LABORATORIES LIMITED (IN) | 2012-03-01 | — | — | US | disclosed |
| WO-2012025942-A1 | METHODS FOR THE TREATMENT OR PROPHYLAXIS OF THROMBOSIS OR EMBOLISM | IPCA LABORATORIES LIMITED (IN) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018331-A1 | METHODS FOR THE TREATMENT OR PROPHYLAXIS OF THROMBOSIS OR EMBOLISM | F2, PLAT, SELP | OGG1 550/4885TRPV1 4055/4885KMT2A 4024/4885 |
| US-20120053157-A1 | METHODS FOR THE TREATMENT OR PROPHYLAXIS OF THROMBOSIS OR EMBOLISM | F2, PLAT, SELP | OGG1 550/4885TRPV1 4055/4885KMT2A 4024/4885 |
| US-20150307513-A1 | COMPOSITION FOR THE TREATMENT OR PROPHYLAXIS OF THROMBOSIS OR EMBOLISM | PLA2G7, F2, PLTP | OGG1 3622/4885TRPV1 4292/4885KMT2A 3421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.